Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma

Vishwa Jeet Amatya, Yukio Takeshima, Hidekazu Kohno, Kei Kushitani, Taketo Yamada, Chikao Morimoto, Kouki Inai

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Aims: The incidence of mesothelioma is increasing in Europe, Japan and other developing countries. There is difficulty in the accurate diagnosis of mesothelioma and its differentiation from lung adenocarcinoma. Mesothelioma shows a complex immunohistochemical profile. Therefore, the use of a immunohistochemical panel that includes both positive and negative mesothelial markers has become a general rule for its accurate diagnosis. However, they are still not sufficient. The aim was to assess the diagnostic utility of caveolin-1 (Cav-1), which is expressed in endothelial cells, alveolar type I pneumocytes and mesothelial cells, as a novel positive marker of mesothelioma. Methods and results: An immunohistochemical study of 80 cases of epithelioid mesothelioma and 80 cases of lung adenocarcinoma was performed for the analysis of the expression of Cav-1 and other markers. Cav-1 expression with a membranous and / or cytoplasmic pattern was found in all of the epithelioid mesothelioma. Of these, 42 cases (52.5%) showed Cav-1 expression in >50% of tumour cells, 34 cases (42.5%) in 650% of tumour cells, and four cases (5.0%) in <5% of tumour cells. In contrast, only six cases (7.5%) of lung adenocarcinoma showed focal Cav-1 expression in the cytoplasm of the tumour cells. The sensitivity and specificity of Cav-1 expression for the differentiation of epithelioid mesothelioma from lung adenocarcinoma were 100 and 92.5%, respectively. This is comparable or even superior to that of currently available positive markers such as calretinin or D2-40. Conclusions: Cav-1 is a novel immunohistochemical marker for the differentiation of epithelioid mesothelioma from lung adenocarcinoma.

Original languageEnglish
Pages (from-to)10-19
Number of pages10
JournalHistopathology
Volume55
Issue number1
DOIs
Publication statusPublished - 2009 Jul

Fingerprint

Caveolin 1
Mesothelioma
Neoplasms
Calbindin 2
Alveolar Epithelial Cells
Adenocarcinoma of lung
Differentiation Antigens
Developing Countries
Japan
Cytoplasm
Endothelial Cells
Sensitivity and Specificity
Incidence

Keywords

  • Caveolin-1
  • Differential diagnosis
  • Epithelioidmesothelioma
  • Immunohistochemistry
  • Lungadenocarcinoma

ASJC Scopus subject areas

  • Histology
  • Pathology and Forensic Medicine

Cite this

Amatya, V. J., Takeshima, Y., Kohno, H., Kushitani, K., Yamada, T., Morimoto, C., & Inai, K. (2009). Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma. Histopathology, 55(1), 10-19. https://doi.org/10.1111/j.1365-2559.2009.03322.x

Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma. / Amatya, Vishwa Jeet; Takeshima, Yukio; Kohno, Hidekazu; Kushitani, Kei; Yamada, Taketo; Morimoto, Chikao; Inai, Kouki.

In: Histopathology, Vol. 55, No. 1, 07.2009, p. 10-19.

Research output: Contribution to journalArticle

Amatya, VJ, Takeshima, Y, Kohno, H, Kushitani, K, Yamada, T, Morimoto, C & Inai, K 2009, 'Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma', Histopathology, vol. 55, no. 1, pp. 10-19. https://doi.org/10.1111/j.1365-2559.2009.03322.x
Amatya, Vishwa Jeet ; Takeshima, Yukio ; Kohno, Hidekazu ; Kushitani, Kei ; Yamada, Taketo ; Morimoto, Chikao ; Inai, Kouki. / Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma. In: Histopathology. 2009 ; Vol. 55, No. 1. pp. 10-19.
@article{220e8e86b3e34f35a36d359f3eea062c,
title = "Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma",
abstract = "Aims: The incidence of mesothelioma is increasing in Europe, Japan and other developing countries. There is difficulty in the accurate diagnosis of mesothelioma and its differentiation from lung adenocarcinoma. Mesothelioma shows a complex immunohistochemical profile. Therefore, the use of a immunohistochemical panel that includes both positive and negative mesothelial markers has become a general rule for its accurate diagnosis. However, they are still not sufficient. The aim was to assess the diagnostic utility of caveolin-1 (Cav-1), which is expressed in endothelial cells, alveolar type I pneumocytes and mesothelial cells, as a novel positive marker of mesothelioma. Methods and results: An immunohistochemical study of 80 cases of epithelioid mesothelioma and 80 cases of lung adenocarcinoma was performed for the analysis of the expression of Cav-1 and other markers. Cav-1 expression with a membranous and / or cytoplasmic pattern was found in all of the epithelioid mesothelioma. Of these, 42 cases (52.5{\%}) showed Cav-1 expression in >50{\%} of tumour cells, 34 cases (42.5{\%}) in 650{\%} of tumour cells, and four cases (5.0{\%}) in <5{\%} of tumour cells. In contrast, only six cases (7.5{\%}) of lung adenocarcinoma showed focal Cav-1 expression in the cytoplasm of the tumour cells. The sensitivity and specificity of Cav-1 expression for the differentiation of epithelioid mesothelioma from lung adenocarcinoma were 100 and 92.5{\%}, respectively. This is comparable or even superior to that of currently available positive markers such as calretinin or D2-40. Conclusions: Cav-1 is a novel immunohistochemical marker for the differentiation of epithelioid mesothelioma from lung adenocarcinoma.",
keywords = "Caveolin-1, Differential diagnosis, Epithelioidmesothelioma, Immunohistochemistry, Lungadenocarcinoma",
author = "Amatya, {Vishwa Jeet} and Yukio Takeshima and Hidekazu Kohno and Kei Kushitani and Taketo Yamada and Chikao Morimoto and Kouki Inai",
year = "2009",
month = "7",
doi = "10.1111/j.1365-2559.2009.03322.x",
language = "English",
volume = "55",
pages = "10--19",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma

AU - Amatya, Vishwa Jeet

AU - Takeshima, Yukio

AU - Kohno, Hidekazu

AU - Kushitani, Kei

AU - Yamada, Taketo

AU - Morimoto, Chikao

AU - Inai, Kouki

PY - 2009/7

Y1 - 2009/7

N2 - Aims: The incidence of mesothelioma is increasing in Europe, Japan and other developing countries. There is difficulty in the accurate diagnosis of mesothelioma and its differentiation from lung adenocarcinoma. Mesothelioma shows a complex immunohistochemical profile. Therefore, the use of a immunohistochemical panel that includes both positive and negative mesothelial markers has become a general rule for its accurate diagnosis. However, they are still not sufficient. The aim was to assess the diagnostic utility of caveolin-1 (Cav-1), which is expressed in endothelial cells, alveolar type I pneumocytes and mesothelial cells, as a novel positive marker of mesothelioma. Methods and results: An immunohistochemical study of 80 cases of epithelioid mesothelioma and 80 cases of lung adenocarcinoma was performed for the analysis of the expression of Cav-1 and other markers. Cav-1 expression with a membranous and / or cytoplasmic pattern was found in all of the epithelioid mesothelioma. Of these, 42 cases (52.5%) showed Cav-1 expression in >50% of tumour cells, 34 cases (42.5%) in 650% of tumour cells, and four cases (5.0%) in <5% of tumour cells. In contrast, only six cases (7.5%) of lung adenocarcinoma showed focal Cav-1 expression in the cytoplasm of the tumour cells. The sensitivity and specificity of Cav-1 expression for the differentiation of epithelioid mesothelioma from lung adenocarcinoma were 100 and 92.5%, respectively. This is comparable or even superior to that of currently available positive markers such as calretinin or D2-40. Conclusions: Cav-1 is a novel immunohistochemical marker for the differentiation of epithelioid mesothelioma from lung adenocarcinoma.

AB - Aims: The incidence of mesothelioma is increasing in Europe, Japan and other developing countries. There is difficulty in the accurate diagnosis of mesothelioma and its differentiation from lung adenocarcinoma. Mesothelioma shows a complex immunohistochemical profile. Therefore, the use of a immunohistochemical panel that includes both positive and negative mesothelial markers has become a general rule for its accurate diagnosis. However, they are still not sufficient. The aim was to assess the diagnostic utility of caveolin-1 (Cav-1), which is expressed in endothelial cells, alveolar type I pneumocytes and mesothelial cells, as a novel positive marker of mesothelioma. Methods and results: An immunohistochemical study of 80 cases of epithelioid mesothelioma and 80 cases of lung adenocarcinoma was performed for the analysis of the expression of Cav-1 and other markers. Cav-1 expression with a membranous and / or cytoplasmic pattern was found in all of the epithelioid mesothelioma. Of these, 42 cases (52.5%) showed Cav-1 expression in >50% of tumour cells, 34 cases (42.5%) in 650% of tumour cells, and four cases (5.0%) in <5% of tumour cells. In contrast, only six cases (7.5%) of lung adenocarcinoma showed focal Cav-1 expression in the cytoplasm of the tumour cells. The sensitivity and specificity of Cav-1 expression for the differentiation of epithelioid mesothelioma from lung adenocarcinoma were 100 and 92.5%, respectively. This is comparable or even superior to that of currently available positive markers such as calretinin or D2-40. Conclusions: Cav-1 is a novel immunohistochemical marker for the differentiation of epithelioid mesothelioma from lung adenocarcinoma.

KW - Caveolin-1

KW - Differential diagnosis

KW - Epithelioidmesothelioma

KW - Immunohistochemistry

KW - Lungadenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=68049123584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68049123584&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2559.2009.03322.x

DO - 10.1111/j.1365-2559.2009.03322.x

M3 - Article

C2 - 19614762

AN - SCOPUS:68049123584

VL - 55

SP - 10

EP - 19

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 1

ER -